Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
June 2, 2025
Labor & Employment Law Perspectives
Update on DHS Efforts to Terminate TPS and Parole Status for Various Immigrant Groups
The U.S. Department of Homeland Security (DHS) has been actively working to terminate Temporary Protected Status (TPS) and Parole status…
June 2, 2025
Labor & Employment Law Perspectives
Circuit Split Deepens on “Harm” as a Failure to Accommodate Element
The split among federal circuit courts of appeal as to whether a disabled worker must show harm in bringing a failure to accommodate…
May 30, 2025
Foley Career Perspectives
Foley Mental Health Month Program: Enhancing Performance Through High-Quality Connections
Foley & Lardner endeavors to create a high-performance culture that also prioritizes well-being — a culture where every member of the…